JOHNSON & JOHNSON
Wall Street traded choppily on Friday after the S&P 500 hit a record close the prior day. Investors weighed July retail sales and consumer sentiment, plus Middle East tensions. Communication services rose on Meta and Alphabet, while chip stocks were mixed and Applied Materials fell after a revenue forecast beat. Energy gained; Amgen and J&J declined.
Johnson & Johnson (JNJ) reported record quarterly results, with sales of $25.3 billion, up 6.6% year over year, according to the company. It raised current fiscal year sales and adjusted EPS guidance and said it is on track to exceed $100 billion in annual revenue for the first time. The article notes JNJ shares are up over 25% in 2026 so far.
Duato Joaquin (CEO and Chairman of the Board) sold 123,291 shares of JOHNSON & JOHNSON (JNJ) at an average of $261.17 ($261.00–$262.00, $32.20M total) across 2 trades on 2026-08-13.
Over the past 7 days, alphai's AI scored 18 news stories mentioning JNJ (JOHNSON & JOHNSON). Coverage has skewed bullish: 9 bullish, 5 neutral, and 4 bearish.
Recent JNJ coverage spans financial news, earnings and corporate actions.
In the last 30 days, JNJ insiders filed 7 SEC Form 4 transactions — no purchases and 7 sales ($54.6M). The most active reporter was Duato Joaquin, CEO and Chairman of the Board, with 4 filings.
JNJ is contributing to Dow weakness, without any new JNJ-specific information.
Guidance increase and record quarterly sales are supportive for near-term sentiment, but the piece reads like a promotional recap rather than a fresh, fully-specified earnings release.
This is a large, non-10b5-1 insider open-market sale by the CEO, which can modestly affect sentiment but is not a fundamental catalyst.
Near-term demand optics for JNJ’s COVID vaccine in Detroit are negative, but the article frames it as temporary and doses were reallocated within Michigan.
Q2 beat and multiple product launch/uptake updates support near-term sentiment, but Stelara biosimilar pressure and LOE remain key offset risks.
alphai scores every news story that mentions JNJ with an AI model for sentiment and relevance, and aggregates insider trades from JOHNSON & JOHNSON's SEC EDGAR Form 4 filings. Figures refresh continuously.
Wall Street traded choppily on Friday after the S&P 500 hit a record close the prior day. Investors weighed July retail sales and consumer sentiment, plus Middle East tensions. Communication services rose on Meta and Alphabet, while chip stocks were mixed and Applied Materials fell after a revenue forecast beat. Energy gained; Amgen and J&J declined.
4 min readJohnson & Johnson (JNJ) reported record quarterly results, with sales of $25.3 billion, up 6.6% year over year, according to the company. It raised current fiscal year sales and adjusted EPS guidance and said it is on track to exceed $100 billion in annual revenue for the first time. The article notes JNJ shares are up over 25% in 2026 so far.
3 min readDuato Joaquin (CEO and Chairman of the Board) sold 123,291 shares of JOHNSON & JOHNSON (JNJ) at an average of $261.17 ($261.00–$262.00, $32.20M total) across 2 trades on 2026-08-13.
2 min readDetroit Mayor Mike Duggan said the city declined 6,200 Johnson & Johnson COVID-19 vaccine doses this week, preferring Pfizer and Moderna. The doses were redirected to other Michigan health departments, according to the state. The White House COVID-19 team said Duggan’s comments were misunderstood. Detroit expects 25,000 to 30,000 more Pfizer/Moderna doses next week.
4 min readJohnson & Johnson (JNJ) shares were up about 4.8% since its last earnings report, after Q2 results. J&J reported adjusted EPS of $2.90 vs $2.84 expected, and sales of $25.3B vs $25.1B. Growth was driven by Innovative Medicines and MedTech, while Stelara declined on biosimilar pressure.
6 min readThe article compares Johnson & Johnson (JNJ) and AbbVie (ABBV) on dividends and recent results. JNJ reported Q2 worldwide sales of $25.3B and highlights a 64-year dividend increase streak with a 2.02% yield. ABBV reported nearly $17B revenue, a 2.78% yield, Skyrizi up 24% to $5.5B, Humira down 36.1% to $706M, and a $10.9B Apogee Therapeutics acquisition that reduces 2026 EPS by $0.14.
6 min readJohnson & Johnson (NYSE:JNJ) agreed to a proposed $5.5B settlement of talc lawsuits alleging its talc products caused ovarian cancer, covering nearly 80,000 claims, according to the company. The article notes a federal judge questioned some expert testimony and disqualified a plaintiffs’ firm. It compares JNJ with AbbVie (NYSE:ABBV) and cites hedge fund and short-interest data.
6 min readThe article compares Johnson & Johnson and AbbVie, focusing on AbbVie’s $10.9 billion Apogee Therapeutics acquisition and its impact on 2026 EPS, and on J&J’s upcoming product and corporate milestones. It cites AbbVie’s long-term outlook and discusses valuation metrics and dividend safety, including J&J’s dividend streak and AbbVie’s higher yield.
6 min readJohnson & Johnson (JNJ) plans to spin off its orthopaedics division into a stand-alone company, DePuy Synthes, targeted for completion 18 to 24 months after an Oct. 2025 announcement. JNJ reported Q2 2026 sales of $25.3B, adjusted EPS $2.90, and raised 2026 guidance to $100.8B-$101.4B sales. It also cited a $50B oncology sales target by 2030 and a Dec. 8 Enterprise Business Review.
5 min readBlackRock (BLK) and Citigroup (C) reported 13F filings showing increased exposure to AI infrastructure in Q2 2026. BlackRock’s U.S. equity holdings rose to about $6.73T. NVIDIA, Apple and Microsoft remained top holdings, while Micron, AMD, Applied Materials and other semiconductor names saw major adds. The article cites cloud-capex procurement commitments near $2T in Q2.
6 min read
